Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of Item Banks to Assess Financial Hardship in Cancer Survivors Using Item Response Theory.

Frontiers in cancer control and society·2026
Same author

Real-World Practice Patterns in Diagnosis and First-Line Treatment in Metastatic Breast Cancer.

The breast journal·2026
Same author

Diversity and functional group composition drive biogeographic patterns in marine biogenic structural complexity.

Ecology·2026
Same author

Preexisting Humoral Immunity Against Seasonal Coronaviruses Enhances Antibody Responses on SARS-CoV-2 Vaccination.

Open forum infectious diseases·2026
Same author

Seasonal differences in predation risk among seagrass epifauna species stabilize community-level predation over time.

Ecology·2026
Same author

Enteroblastic and Hepatoid Colorectal Carcinomas are Aggressive Cancers With a Distinctive Immunophenotype, While Clear Cell Carcinoma Appears to Represent Clear Cell Change in Conventional Colorectal Cancer.

The American journal of surgical pathology·2026

Related Experiment Video

Updated: Feb 24, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.3K

CD200 Expression in Neuroendocrine Neoplasms.

Jason E Love1, Kimberly Thompson2, Mark R Kilgore3

  • 1Western Washington Pathology, Tacoma.

American Journal of Clinical Pathology
|August 20, 2017
PubMed
Summary

CD200 is a sensitive marker for neuroendocrine neoplasms, found in 87% of cases studied. This finding highlights CD200 as a potential therapeutic target for these challenging cancers.

Keywords:
CD200ImmunohistochemistryNeuroendocrine neoplasms

More Related Videos

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K
Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
07:01

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Published on: March 1, 2020

10.9K

Related Experiment Videos

Last Updated: Feb 24, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.3K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K
Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
07:01

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Published on: March 1, 2020

10.9K

Area of Science:

  • Oncology
  • Immunohistochemistry
  • Molecular Diagnostics

Background:

  • CD200 expression is well-documented in blood cancers.
  • CD200 expression is poorly understood in neuroendocrine neoplasms (NENs).

Purpose of the Study:

  • To characterize CD200 expression across diverse neuroendocrine neoplasms.
  • To assess CD200 as a potential diagnostic marker and therapeutic target in NENs.

Main Methods:

  • Immunohistochemistry was used to evaluate CD200 expression.
  • 391 NENs from various sites were analyzed.
  • Non-neuroendocrine carcinomas served as a control group.

Main Results:

  • CD200 was expressed in 87% of all NENs analyzed.
  • High CD200 expression was observed in pulmonary small cell carcinoma, Merkel cell carcinoma, gastrointestinal carcinoid, and pancreatic neuroendocrine tumors.
  • CD200 expression was significantly lower in non-NENs (20%).
  • CD200 negativity correlated with higher grade in gastrointestinal carcinoid and pancreatic NENs.

Conclusions:

  • CD200 is a sensitive marker for identifying neuroendocrine neoplasms.
  • CD200 represents a promising therapeutic target for difficult-to-treat NENs.